Lifeboat Foundation

Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery.

On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of Foresite Capital, announced that they incubated Xaira Therapeutics and funded the AI biotech with $1 billion. Other investors in the new company, which has been operating in stealth mode for about six months, include F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures and SV Angel.

Xaira’s CEO Marc Tessier-Lavigne, a former Stanford president and chief scientific officer at Genentech, says the company is ready to start developing drugs that were impossible to make without recent breakthroughs in AI. “We’ve done such a large capital raise because we believe the technology is at an inflection point where it can have a transformative effect on the field,” he said.

The single-celled organism Naegleria fowleri ranks among the deadliest human parasites. Matthias Horn and Patrick Arthofer of the University of Vienna’s Center for Microbiology and Environmental Systems Science, along with other researchers, have identified viruses that target this dangerous organism.

Named Naegleriavirus, these belong to the giant viruses, a group known for their unusually large particles and complex genomes. The team details their findings in the prestigious journal, Nature Communications.

Naegleri species are single-celled amoebae, found globally in water bodies. Notably, one species, Naegleria fowleri, thrives in warm waters above 30°C and causes primary amoebic meningoencephalitis (PAM), a rare but almost invariably fatal brain infection. A research team led by Patrick Arthofer and Matthias Horn from the University of Vienna’s Center for Microbiology and Environmental Systems Science (CeMESS) has now isolated giant viruses that infect various Naegleria species.

The new technology, which was created at the University of Turku and developed by the company CardioSignal, uses a smartphone to analyse heart movement and detect heart failure. The study involved five organisations from Finland and the United States.

Heart failure is a condition affecting tens of millions of people worldwide, in which the heart is unable to perform its normal function of pumping blood to the body.

It is a serious condition that develops as a result of a number of cardiovascular diseases and its symptoms may require repeated hospitalisation.

Pacemakers are medical devices that make sure that someone’s heart beats the way it should. If the heart rhythm is off, the pacemaker delivers a surge of electricity to bring the heart back into rhythm. The pacemaker takes effort into account and delivers faster pulses when needed. For example, when you’re exercising. For these electric pulses, the pacemaker needs a capacitor to rapidly charge and discharge. This provides a high enough electric charge to reset the heart.

Researcher Minh Duc Nguyen and his colleagues worked on a new design strategy for these capacitors to improve their energy storage, decrease the amount of energy lost every time it is charged or discharged, and increase the number of times they can reliably charge and discharge.

“It needs to keep up with your heartbeat, so it should be able to charge and discharge up to billions of times. Otherwise, you’ll have to replace the pacemaker every few months”, explains Nguyen.

Scientists have successfully engineered functional artificial cells in the lab that behave like living cells.

Advances in the development of cytoskeletal-like materials with modular structures and mechanics are pivotal for the engineering of synthetic cells. Now actin-mimetic supramolecular peptide networks have been designed using programmable peptide–DNA crosslinkers, giving rise to tunable tactoid-shaped bundles and mechanical properties that control spatial localization, the diffusion of payloads and shape changes within artificial cells.

Read how Congress is pressing the DEA to reclassify marijuana from a Schedule I drug to Schedule III.

Marijuana is currently classified as a Schedule I drug, meaning these are “drugs with no currently accepted medical use and a high potential for abuse.” However, a team of 21 bipartisan congressional leaders from both the Senate and House of Representatives hopes to change that as they recently sent a letter to the United States Drug Enforcement Administration (DEA) pushing them to “promptly remove marijuana from Schedule I of the Controlled Substances Act (CSA)”, noting that almost eight months had passed “since the Department of Health and Human Services (HHS) recommended rescheduling marijuana to Schedule III — and 18 months since President Biden directed HHS and the Department of Justice (DOJ) to begin the process of reviewing marijuana’s scheduling.”

Examples of other Schedule I drugs include heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote, while Schedule III drugs include Tylenol, ketamine, anabolic steroids, and testosterone. Additionally, the penalties between Schedule I and Schedule III drugs also demonstrate stark contrasts, as well.

Continue reading “Bipartisan Effort Demands DEA Action on Marijuana Scheduling” »

Chemotherapy is the treatment of choice before most cancer surgeries, but a study from the Albert Einstein College of Medicine of Yeshiva University in New York, using data from mouse models demonstrated that chemotherapy can paradoxically enhance cancer progression.

A newly developed nanomaterial that mimics the behavior of proteins could be an effective tool for treating Alzheimer’s and other neurodegenerative diseases. The nanomaterial alters the interaction between two key proteins in brain cells—with a potentially powerful therapeutic effect.

The innovative findings, recently published in the journal Advanced Materials, were made possible thanks to a collaboration between University of Wisconsin–Madison scientists and nanomaterial engineers at Northwestern University.

The work centers around altering the interaction between two proteins that are believed to be involved in setting the stage for diseases like Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis, or ALS.

A New Jersey woman is the second living recipient of a pig kidney.